On September 6, Chengdu Kanghua Biological Products stated on the interactive platform that the company actively implements the overseas strategy. The company's ongoing project, the recombinant hexavalent norovirus vaccine, has achieved technology outflow through the signing of a licensing agreement, and has received an upfront payment of $15 million. The company's ACYW135 group meningococcal polysaccharide vaccine has achieved product export.
康华生物：公司ACYW135群脑膜炎球菌多糖疫苗已实现产品出口
Chengdu Kanghua Biological Products: The company's ACYW135 group meningococcal polysaccharide vaccine has achieved product export.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.